Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma  by Chang, Tzu-Pei & Vancurova, Ivana
Biochimica et Biophysica Acta 1843 (2014) 2620–2630
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrBcl3 regulates pro-survival and pro-inﬂammatory gene expression in
cutaneous T-cell lymphomaTzu-Pei Chang, Ivana Vancurova ⁎
Department of Biological Sciences, St. John's University, New York, NY 11439, USAAbbreviations: Bcl3, B-cell chronic lymphatic leukem
ChIP, chromatin immunoprecipitation; CTCL, cutaneous
fungoides; SS, Sézary syndrome
⁎ Corresponding author at: Department of Biological
8000 Utopia Parkway, Queens, NY 11439, USA. Tel.: +1 7
5958.
E-mail address: vancuroi@stjohns.edu (I. Vancurova).
http://dx.doi.org/10.1016/j.bbamcr.2014.07.012
0167-4889/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 2 June 2014
Received in revised form 15 July 2014
Accepted 21 July 2014
Available online 30 July 2014
Keywords:
Bcl3
Bortezomib
Cutaneous T-cell lymphoma
NFκB
Pro-inﬂammatory cytokineThe advanced stages of cutaneous T cell lymphoma (CTCL) are characterized not only by decreased levels of pro-
inﬂammatory cytokines, resulting in high susceptibility to infections, but also by high constitutive activity of
NFκB, which promotes cell survival and resistance to apoptosis. The increased expression of the proto-
oncogene Bcl3 belonging to IκB family is associatedwith the pathogenesis of the different types of human cancer,
yet, the function and regulation of Bcl3 in CTCL have not been studied. Here, we show that Bcl3 is highly
expressed in CTCL Hut-78 and HH cells. The suppression of Bcl3 levels decreases the expression of the pro-
survival genes cIAP1 and cIAP2, reduces cell viability, and increases CTCL apoptosis. Interestingly,
Bcl3 suppression concomitantly increases expression and the release of the pro-inﬂammatory cytokines IL-8
and IL-17 in CTCL cells. Chromatin immunoprecipitation studies show that Bcl3 regulates cIAP1, cIAP2, IL-8
and IL-17 gene expression through direct binding to their promoters. Bcl3 expression is regulated by bortezomib
(BZ)-mediated proteasome inhibition, and BZ inhibits Bcl3 recruitment to its target promoters, resulting in
decreased expression of cIAP1 and cIAP2, but increased expression of IL-8 and IL-17. The Bcl3 expression is
regulated through NFκB subunit exchange on Bcl3 promoter. In untreated cells, the Bcl3 promoter is occupied
predominantly by p65/p50 heterodimers, inducing Bcl3 expression; however, in BZ-treated cells, the p65/50
heterodimers are replaced by p52 subunits, resulting in Bcl3 transcriptional repression. These data provide the
ﬁrst insights into the function and regulation of Bcl3 in CTCL, and indicate that Bcl3 has an important pro-
survival and immunosuppressive role in these cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cutaneous T-cell lymphoma (CTCL) encompasses a group of
lymphoproliferative disorders characterized by skin invasive neoplastic
T cells. Mycosis fungoides (MF) and the leukemic variant Sézary
syndrome (SS) are themost common clinical forms [1–5]. NFκB activity
is constitutively increased in CTCL, where it induces the expression of
anti-apoptotic genes and resistance to apoptosis, and plays a central
mediator between malignant cell survival and inﬂammatory signaling
[6–11]. The advanced stages of CTCL are associated with suppressed
cell-mediated immunity and decreased levels of pro-inﬂammatory
cytokines, resulting in increased susceptibility to infection [12–17].
Despite the recent advances in elucidating the immune mechanisms
responsible for the pathogenesis of CTCL, there is no effective strategy
to prolong survival in the advanced stages [18–24].ia protein 3; BZ, bortezomib;
T cell lymphoma; MF, mycosis
Sciences, St. John's University,
18 990 6409; fax: +1 718 990Bortezomib (BZ, Velcade, PS-341) is the ﬁrst FDA approved 26S pro-
teasome inhibitor that has beenwidely used in the treatment of patients
withmultiplemyeloma [25–27]. BZ has shown promising results also in
patients with relapsed or refractory CTCL [28–31]. However, the precise
molecular mechanisms are not fully understood. BZ has been originally
developed as the inhibitor of inducible NFκB activity and NFκB-
dependent transcription [25–27]. Interestingly, however, recent studies
have shown that the BZ effect on NFκB-dependent transcription is gene
speciﬁc;while some genes are inhibited, some are unaffected, and some
genes are actually increased, depending on the subunit composition of
NFκB dimers recruited to NFκB-responsive promoters [32–35].
B-cell chronic lymphatic leukemia protein 3 (Bcl3) is a member of
IκB family that was ﬁrst identiﬁed as a candidate proto-oncogene in
somepatientswith chronic lymphocytic leukemia [36]. However, unlike
other IκBs, Bcl3 is a predominantly nuclear protein, which contains a
transactivation domain, and can be recruited to NFκB-responsive pro-
moters, resulting in transcriptional activation or repression, depending
on the subunit composition of NFκB complexes [37–43]. Elevated Bcl3
expression results in increased cell proliferation, survival andmalignant
potential. Studies have demonstrated increased Bcl3 expression in the
different types of hematopoietic and solid cancers [44–49], yet its
function and regulation in CTCL have not been investigated.
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tion of Bcl3 in human CTCL cells. We show that Bcl3 is highly expressed
in CTCL Hut-78 andHH cells, and its suppression inhibits the expression
of anti-apoptotic genes cIAP1 and cIAP2, but increases the expression
of pro-inﬂammatory cytokines IL-8 and IL-17, indicating that Bcl3 has
a pro-survival and immuno-suppressive function in CTCL cells. We fur-
ther demonstrate that Bcl3 expression is regulated by the BZ-mediated
proteasome inhibition and by the subunit exchange of NFκB proteins.
These ﬁndings provide the ﬁrst insights into the function and regulation
of Bcl3 in CTCL, and identify Bcl3 as a new potential target in the CTCL
treatment.2. Materials and methods
2.1. Antibodies and reagents
Puriﬁed polyclonal antibodies against human Bcl3 (sc-185), Bcl2
(sc-492), NFκB p65 (sc-372X), NFκB p50 (sc-7178X), cRel (sc-71X),
RelB (sc-226X), NFκB p52 (sc-848X), and lamin B (sc-6216) were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Puriﬁed
polyclonal antibody against lactate dehydrogenase (LDH; 20-LG22)
was from Fitzgerald Industries International (Concord, MA, USA), and
actin antibodywas from Sigma (St. Louis, MO, USA). Horseradish perox-
idase (HRP)-conjugated anti-rabbit, anti-mouse and anti-goat second-
ary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).
Bortezomibwas purchased fromChemieTek (Indianapolis, IN, USA). Re-
combinant human IL-8 and IL-17 proteinswere fromR&D(Minneapolis,
MN, USA). All other reagents were molecular biology grade and were
from Sigma (St. Louis, MO).2.2. Cell culture
CTCL cell lines, Hut-78 (ATCC® TIB-161) and HH (ATCC® CRL-2105)
cells, derived from the peripheral blood of patients with SS and non-
MF/SS aggressive CTCL respectively, as well as monocytic leukemia
U937 (ATCC® CRL-1593.2) and THP-1 (ATCC® TIB-202) cells were
obtained from and validated by the American Type Culture Collection
(ATCC; Rockville, MD, USA), and used between the passage numbers
10 and 15. Peripheral blood mononuclear cells (PBMC) from healthy
human volunteers were purchased from AllCells (PB003F; Alameda, CA,
USA). Cells were maintained at 37 °C in RPMI 1640 medium, supple-
mented with 10% heat inactivated fetal bovine serum (FBS) and 2 mM
L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, in a
humidiﬁed atmosphere with 5% CO2. Prior to cell treatment, cells were
seeded (5 × 105 cells/ml) in 6-well plates and grown 24 h at 37 °C
with 5% CO2. Bortezomib was dissolved in DMSO and stored at−80 °C.
An equivalent volume of DMSO was used in all experiments as a solvent
control. Cell viability was measured by using Trypan Blue exclusion.2.3. Transfections
Prior to transfections, cells were seeded (5×105 cells/ml) into a 6-
well plate and incubated in a humidiﬁed 5% CO2 atmosphere at 37 °C
in antibiotic-free RPMI medium supplemented with 10% FBS for 24 h.
For siRNA transfections, 50 nmol (ﬁnal concentration) of control
siRNA-A (sc-37007; Santa Cruz Biotechnology, CA, USA) or Bcl3 siRNA
(sc-29789) was used. Cells were transfected with TransIT-siQUEST
transfection reagent (Mirus Bio, Madison, WI, USA) according to the
manufacturer's instructions. For shRNA transfections, 2.5 μg of control
shRNA-A (sc-108060) or Bcl3 shRNA plasmid (sc-29789-SH) was
used, and cells were transiently transfected with TransIT-Jurkat trans-
fections reagent (Mirus Bio) according to the manufacturer's instruc-
tions. After transfection, fresh RPMI medium supplemented with FBS
and antibiotics was added and cells were incubated for 48 h.2.4. Preparation of whole cell extracts, cytoplasmic and nuclear extracts,
and western blotting
Whole cell extracts, and nuclear (NE) and cytoplasmic extracts (CE)
were prepared as described previously [33–35], and separated on 12%
SDSgels. To determine equal protein loading,membraneswere stripped
and re-probed with anti-actin antibody as described [34,35]. The
contamination of nuclear and cytoplasmic fractions by cytoplasmic
and nuclear proteins, respectively, was determined by western analysis
using lactate dehydrogenase (LDH) and lamin B as speciﬁc markers as
described [34,35].2.5. Real time RT-PCR
Total RNA was isolated by using RNeasy mini-kit (Qiagen, Valencia,
CA, USA). The iScript one-step RT-PCR kit with SYBR Green (BioRad,
Hercules, CA, USA) was used as a supermix and 20 ng of RNA was
used as template on a Bio-Rad MyIQ Single Color Real-Time PCR Detec-
tion System (BioRad). The primers used for the quantiﬁcation of Bcl3,
cIAP1, cIAP2, Bcl2, IL-8, IL-17, and actin mRNA were purchased from
SA Biosciences (Frederick, MD, USA).2.6. Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed as described previously [34,35]. Brieﬂy,
proteins and DNA were cross-linked by formaldehyde, cells were
washed and sonicated. The lysates were centrifuged (15,000 g, 10 min,
4 °C), and the supernatant extractswere dilutedwith ChIP dilution buff-
er and pre-cleared with Protein A/G Agarose (Santa Cruz, CA) for 2 h at
4 °C. Immunoprecipitation was performed overnight at 4 °C, with Bcl3,
p65, p50, cRel, RelB or p52 antibodies. Following immunoprecipitation,
the samples were incubated with Protein A/G Agarose (1 h, 4 °C), and
the immune complexes were collected by centrifugation (150 g,
5 min, 4 °C), washed, and extracted with 1% SDS–0.1 M NaHCO3. After
reversing the cross-linking, proteins were digested with proteinase K,
and the samples were extracted with phenol/chloroform, followed by
precipitation with ethanol. The pellets were resuspended in nuclease-
free water and subjected to real time PCR. Immunoprecipitated DNA
was analyzed by real-time PCR (25 μl reaction mixture) using the iQ
SYBR Green Supermix and the Bio-Rad MyIQ Single Color Real-Time
PCR Detection System (Bio-Rad). Each immunoprecipitation was per-
formed four times using different chromatin samples, and the occupan-
cy was calculated by using the ChIP-qPCR Human IGX1A Negative
Control Assay (SA Biosciences, Frederick, MD) as a negative control
and corrected for the efﬁciency of the primers, which detect speciﬁc
genomic DNA sequences within ORF-free intergenic regions or “pro-
moter deserts” lacking any known or predicted structural genes. The
ChIP primers for IL-8 and IL-17 were purchased from Qiagen (Valencia,
CA, USA). The ChIP primers for Bcl3, cIAP1, cIAP2 and Bcl2 were the
following: Bcl3: forward, 5′-TTGCGGAGAGAAACACCTACT-3′ and
reverse, 5′-CGCTCTC-TCTGCCTCTGTT-3′; cIAP1: forward, 5′-TGACTG
GCAGGCAGAAATGA-3′ and reverse, 5′-TTTGCCCGTTGAATCCGAT-3′;
cIAP2: forward, 5′-TTCAGTAAATGCCGCGAAGAT-3′ and reverse, 5′-
TGGTTTGCATGTGCACTGGT-3′; and Bcl2: forward, 5′-TGCATCTCAT
GCC-AAGGG-3′ and reverse, 5′-CCCCAGAGAAAGAAGAGGAGTT-3.2.7. Apoptosis assay
Apoptosis was evaluated with a cell death detection ELISA kit that
quantiﬁes the release of nucleosomes into the cytoplasm (Cell Death
Detection ELISAPLUS, Roche, Indianapolis, IN, USA) as described [32].
The assay was performed at the indicated time points as per the
manufacturer's instructions.
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Cytokine release was measured in cell culture supernatants by
commercially available ELISA kits (R&D, Minneapolis, MN, USA) as pre-
viously described [34,35].
2.9. Statistical analysis
The results represent at least three independent experiments.
Numerical results are presented as means ± SE. Data were analyzed
by using an InStat software package (GraphPAD, San Diego, CA, USA).
Statistical signiﬁcance was evaluated by using Mann–Whitney U test
with Bonferroni correction for multiple comparisons, and p b 0.05 was
considered signiﬁcant.
3. Results
3.1. Bcl3 is highly expressed in CTCL cells, and its expression is inhibited
by BZ
To determine whether Bcl3 is expressed in CTCL cells and whether
its expression is regulated by proteasome, we have analyzed the Bcl3
protein levels in whole cell extracts prepared from CTCL Hut-78 and
HH cells incubated 24 h with increasing BZ concentrations. As shownA
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cells, and proteasome inhibition by BZ decreases its protein levels in
both cell lines. BZ also signiﬁcantly suppressed Bcl3 mRNA levels in
CTCL cells. Compared to untreated cells, 100 nM BZ that approximately
corresponds to the clinically used BZ concentrations [50], inhibited
more than 90% of Bcl3 mRNA expression in Hut-78 cells (Fig. 1C). The
inhibition of Bcl3mRNA expression by BZwas time dependent (Fig. 1D).
To compare the Bcl3 protein levels in CTCL cells to other leukocytes,
we have analyzed the Bcl3 expression in CTCL Hut-78 and HH cells, in
monocytic leukemia cell lines U937 and THP1, and in normal human
peripheral blood mononuclear cells (PBMC). As shown in Fig. 1E,
compared to the monocytic U937 and THP1 cells and normal human
PBMC, the CTCL Hut-78 and HH cell lines express considerably more
Bcl3.
3.2. Suppression of Bcl3 regulates survival in CTCL cells
To obtain a ﬁrst insight into the Bcl3 function in CTCL, we have ana-
lyzed cell viability and cytoplasmic nucleosome enrichment in Hut-78
cells transfected with Bcl3 siRNA, as well as with control non-silencing
siRNA. Transfection with Bcl3 siRNA resulted in approximately 70% re-
duction in total cellular Bcl3 protein levels compared to cells transfected
with control non-silencing siRNA (Fig. 2A, B). The suppression of Bcl3
resulted in approximately 40% decreasedHut-78 cell viabilitymeasuredB
0
25
50
75
100
125
0 6 24 48
B
cl
3 
m
R
N
A
 (%
 U
T)
Time (h)
* *
*
BZ (nM)   0      1   10   100
Bcl3
Actin
U937    THP1   PBMC     
D
tting of whole cell extracts prepared from CTCL Hut-78 (A) and HH cells (B) treated with
ual protein loading, the membranes were stripped and re-probed with actin antibody.
RNA levels in Hut-78 cells treated 24 h with increasing BZ concentrations. (D) Real time
The values represent the mean ± SE of four experiments. Asterisks denote a statistically
g of whole cell extracts prepared from Hut-78, HH, U937, THP1 and PBMC cells analyzed
A B
C D
Bcl3
Actin
siRNA-control +        -
siRNA-Bcl3 - +
0
25
50
75
100
125
siRNA-control siRNA-Bcl3
Bc
l3
/A
ct
in
 (%
)
*    
0
25
50
75
100
125
siRNA-control siRNA-Bcl3
C
el
l v
ia
bi
lit
y 
(%
)
*
0.0
0.5
1.0
1.5
2.0
siRNA-control siRNA-Bcl3
*
N
uc
le
os
om
e 
en
ric
hm
en
t
Fig. 2. Bcl3 suppression induces apoptosis in CTCL cells. (A) Western blotting of whole cell extracts prepared from Hut-78 cells transfected with control non-silencing and Bcl3
speciﬁc siRNA, and analyzed by using Bcl3 and actin speciﬁc antibodies. (B) Densitometric evaluation of Bcl3 densities showed in panel A. The Bcl3/actin value in cells transfected with
control siRNA was arbitrarily set to 100%, and the Bcl3/actin value in cells transfectedwith Bcl3 siRNA is presented relative to this value. The data represent themean of four experiments
± SE, and the asterisk denotes a statistically signiﬁcant (p b 0.05) change compared to cells transfected with control siRNA. (C) Cell viability and (D) the cytoplasmic nucleosome enrich-
ment assay in Hut-78 cells transfected with control and Bcl3 siRNA. The values represent the mean ± SE of four experiments; the asterisk denotes a statistically signiﬁcant (p b 0.05)
change compared to cells transfected with control siRNA.
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ment in the cytoplasm, indicating apoptosis (Fig. 2D). These results have
suggested that Bcl3 is involved in the regulation of cell survival in CTCL
cells.
3.3. Suppression of Bcl3 inhibits expression of anti-apoptotic genes, but
increases expression of pro-inﬂammatory genes in CTCL cells
To determine whether Bcl3 regulates pro-survival genes in CTCL
cells, we have analyzed the expression of NFκB-dependent anti-
apoptotic genes cIAP1, cIAP2 and Bcl2 in Hut-78 cells transfected with
Bcl3 speciﬁc siRNA or shRNA, or corresponding non-silencing controls.
Bcl3 suppression by both siRNA and shRNA signiﬁcantly decreased
the mRNA (Fig. 3A) and protein levels (Fig. 3B, C) of cIAP1 and cIAP2,
while Bcl2 levels were not affected, suggesting that Bcl3 increases the
survival of CTCL cells by inducing the transcription of cIAP1 and cIAP2.
In addition to the anti-apoptotic genes, we have investigated the
effect of Bcl3 suppression on the NFκB-dependent pro-inﬂammatory
cytokines IL-8 and IL-17, since both cytokines were implicated in the
pathogenesis of CTCL [51–54]. Interestingly, in contrast to the anti-
apoptotic genes cIAP1 and cIAP2 that were inhibited by Bcl3 suppres-
sion, Bcl3 suppression signiﬁcantly increased both mRNA levels
(Fig. 3A) and cytokine release (Fig. 3D) of IL-8 and IL-17 in Hut-78
cells. Compared to cells transfected with control siRNA and shRNA,
cells transfected with Bcl3 siRNA and shRNA exhibited approximately
2.5 and 3.8 fold higher IL-8 mRNA levels, respectively (Fig. 3A). IL-17
gene expression was increased approximately 3.5 and 4.5 folds in cells
transfected with siRNA and shRNA, respectively, compared to cells
transfected with corresponding controls (Fig. 3A). At the protein level,the IL-8 and IL-17 release was barely detectable in CTCL Hut-78 cells
transfected with control siRNA or shRNA (Fig. 3D). However, the sup-
pression of Bcl3 with siRNA or shRNA increased the IL-8 release to
about 50 and 40 pg/ml, respectively. The IL-17 release was increased
in cells transfected with Bcl3 speciﬁc siRNA or shRNA to approximately
10 and 25 pg/ml, respectively (Fig. 3D). The IL-8 and IL-17 release levels
in Bcl3-suppressed cells are comparable to the IL-8 and IL-17 serum
levels in healthy adults [55–57].
3.4. Bcl3 is recruited to cIAP1, cIAP2, IL-8 and IL-17 promoters in CTCL cells,
and BZ inhibits the Bcl3 recruitment
Bcl3 can be recruited to gene promoters, resulting in transcriptional
repression or activation, depending on the transcription factors or co-
regulators present in the transcriptional complex [58–60]. Since the
mRNA expression of cIAP1, cIAP2, IL-8 and IL-17 was dependent on
Bcl3 (Fig. 3A), we have investigated the possibility that Bcl3 is recruited
to cIAP1, cIAP2, IL-8 and IL-17 promoters in CTCL cells. Hut-78 cellswere
incubated 24 hwith 0 and 10 nMBZ, cross-linked, lysed, and chromatin
was sheared by sonication. Bcl3 recruitment to cIAP1, cIAP2, Bcl2, IL-8
and IL-17 promoters was analyzed by chromatin immunoprecipitation
(ChIP) and quantiﬁed by real time PCR. The NFκB binding sites of the
above genes are shown in Fig. 4A.
Bcl3 was recruited to cIAP1 and cIAP2 (Fig. 4B), and IL-8 and IL-17
(Fig. 4C) promoters in untreated cells, indicating that Bcl3 regulates
the transcription of these genes in CTCL cells. Proteasome inhibition
by 10 nM BZ, which greatly reduced the cellular Bcl3 protein levels
(Fig. 1A), also signiﬁcantly reduced the Bcl3 occupancy at these pro-
moters (Fig. 4B, C). In contrast, Bcl3 was not recruited to Bcl2 promoter
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Fig. 3. Suppression of Bcl3 inhibits expression of anti-apoptotic genes, but induces expression of pro-inﬂammatory genes in CTCL cells. (A) Real time RT-PCR analysis of cIAP1, cIAP2, Bcl2,
IL-8 and IL-17mRNA levels in Hut-78 cells transfectedwith control non-silencing siRNA or shRNA (full columns), and Bcl3 speciﬁc siRNA (empty columns) or shRNA (gray columns). The
values represent the mean ± SE of four experiments. Asterisks denote a statistically signiﬁcant (p b 0.05) change compared to cells transfected with the corresponding control RNA.
(B) Western analysis of total protein levels of Bcl3, cIAP1, cIAP2, Bcl2, and control actin, in Hut-78 cells transfected with control non-silencing and Bcl3 speciﬁc siRNA or shRNA.
(C) Densitometric evaluation of cIAP1, cIAP2 and Bcl2 densities shown in panel B. The cIAP1, cIAP2 and Bcl2 protein/actin values in cells transfected with control RNA were arbitrarily
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represent the mean ± SE of four experiments. Asterisks denote a statistically signiﬁcant (p b 0.05) change compared to cells transfected with the corresponding controls.
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not regulate the Bcl2 expression in CTCL cells (Fig. 3A).
3.5. BZ-mediated proteasome inhibition induces IL-8 and IL-17 expression
in CTCL cells
Since BZ decreased the Bcl3 recruitment to IL-8 and IL-17 promoters
(Fig. 4C), and Bcl3 suppression increased the IL-8 and IL-17 expression
(Fig. 3A, D), we hypothesized that proteasome inhibition by BZ might
increase the IL-8 and IL-17 expression in CTCL cells. To test this possibil-
ity, we have analyzed IL-8 and IL-17 mRNA levels and cytokine release
in Hut-78 and HH cells treated 24 h with increasing BZ concentrations.
Indeed, BZ signiﬁcantly increased IL-8 and IL-17 mRNA levels in both
CTCL cell types (Fig. 5A, B). Furthermore, BZ also increased the IL-18
and IL-17 release from CTCL cells (Fig. 5C, D). In untreated Hut-78 and
HH cells, the IL-8 and IL-17 release levels were barely detectable,
which is in an agreement with the immunosuppressive nature of
these cells [61]. However, 100 nM BZ increased the IL-8 and IL-17 re-
lease levels in both CTCL cells to about 60 and 15 pg/ml, respectively
(Fig. 5C, D).
To investigate whether the BZ-increased IL-8 and IL-17 release
might directly affect the CTCL cell viability, we havemeasured the effect
of recombinant human IL-8 and IL-17 proteins on the viability of Hut-78
cells. As shown in Fig. 5E and F, 50 and 15 pg/ml concentrations of
IL-8 and IL-17, which are approximately induced by 100 nM BZ in
Hut-78 cells (Fig. 5C, D), decrease the CTCL cell viability by about 10%,
suggesting that the BZ-induced IL-8 and IL-17 might contribute to the
previously observed BZ-mediated inhibition of CTCL cell viability [30].3.6. Bcl3 mediates the BZ-induced IL-8 and IL-17 expression, and cIAP1 and
cIAP2 inhibition
Our results have suggested that the BZ-induced expression of IL-8
and IL-17, and the inhibition of cIAP1 and cIAP2 are mediated, at least
partly, by Bcl3. To test this hypothesis, we have transfected Hut-78
cells with Bcl3 (or control) siRNA, and then incubated 24 h with 0, 10
and 100 nM BZ. The suppression of Bcl3 expression further decreased
Hut-78 cell viability in BZ-treated cells (Fig. 6A). In addition, the
suppression of Bcl3 signiﬁcantly decreased cIAP1 and cIAP2 mRNA
(Fig. 6B), and increased IL-8 and IL-17 mRNA levels (Fig. 6C) in BZ-
treated cells. In contrast, Bcl3 suppression did not have any signiﬁcant
effect on the Bcl2 mRNA levels in BZ-treated Hut-78 cells (Fig. 6B);
this is in a good agreement with the data demonstrating that Bcl3 is
not recruited to Bcl2 promoter (Fig. 4B) and Bcl2 expression is not
regulated by BZ [33]. These results indicate that the BZ-induced IL-8
and IL-17 expression, and cIAP1 and cIAP2 inhibition in Hut-78 cells,
are mediated by Bcl3.3.7. The BZ-mediated inhibition of Bcl3 expression is associated with
decreased recruitment of p65 and p50, but increased recruitment of p52,
to Bcl3 promoter in CTCL cells
Since previous studies have suggested that Bcl3 expression is regu-
lated by NFκB [62,63], we wanted to determine which NFκB subunits
regulate the Bcl3 transcription in CTCL cells. To this end, we have ﬁrst
analyzed which NFκB subunits are localized in the nucleus in Hut-78
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ments. Asterisks denote a statistically signiﬁcant (p b 0.05) change compared to untreated
cells.
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and in the nucleus in untreated cells, but 10 and 100 nM BZ reduced
the RelB nuclear levels. In contrast, while cRel and p52 were localized
mainly in the cytoplasm in untreated cells, 100 nM BZ increased their
nuclear accumulation, especially that of p52 (Fig. 7A).To determine whether the nuclear NFκB subunits are recruited to
the Bcl3 promoter, we have analyzed the human Bcl3 promoter using
TFSEARCH program for searching transcription factor binding sites
[64], and we have identiﬁed a new potential NFκB binding site in the
Bcl3 promoter (Fig. 7B). This site (5′-GGGACACCCC-3′) shows a high
homology to the consensus NFκB site 5′-GGGRNWYYCC-3′, where R
is purine, N is any nucleotide, W is adenine or thymine, and Y is pyrim-
idine. Using ChIP, we have analyzed the recruitment of p65, p50,
cRel, RelB and p52 to the Bcl3 promoter in Hut-78 cells incubated 24 h
with 0, 10 and 100 nM BZ. As shown in Fig. 7C, both p65 and p50
NFκB were heavily recruited to the Bcl3 promoter in untreated cells,
indicating that the Bcl3 promoter site is occupied by NFκB p65/p50
heterodimers, resulting in the high Bcl3 expression in untreated CTCL
cells. Proteasome inhibition by BZ almost completely inhibited the
recruitment of p65 and p50 (Fig. 7C), despite their high levels in the
nucleus (Fig. 7A). These ﬁndings suggest that the high expression of
Bcl3 in CTCL cells is mediated by p65/p50 heterodimers, and that pro-
teasome inhibition suppresses the Bcl3 transcription by inhibiting the
p65/p50 recruitment.
Unlike p65 and p50, the recruitment of cRel and RelB was low, and
was not affected by BZ, indicating that the Bcl3 transcription in CTCL
cells is not regulated by cRel or RelB. Interestingly however, even though
the recruitment of p52 to Bcl3 promoter was low in untreated cells, it
was signiﬁcantly increased in 100 nM BZ-treated cells (Fig. 7C), sug-
gesting that proteasome inhibition replaces p65/p50 heterodimers
with p52 subunits, resulting in the transcriptional repression of Bcl3
(Fig. 7D).
4. Discussion
The advanced stages of CTCL are characterized not only by the in-
creased survival of malignant T cells and their resistance to apoptosis,
but also by severe immunodeﬁciency that is associated with the
decreased production of pro-inﬂammatory cytokines [1–4]. Here, we
have analyzed the function and regulation of the proto-oncogene and
transcriptional regulator Bcl3, which has been associatedwith the path-
ogenesis of the different types of human cancer, but its regulation and
function in CTCL have never been investigated.We show that compared
to other leukocytes including normal human PBMC, Bcl3 is highly
expressed in CTCL Hut-78 and HH cells (Fig. 1). The Bcl3 expression in
CTCL is further supported by previous studies indicating increased
Bcl3 gene expression in about 50% of CTCL patients [44], and increased
Bcl3 protein levels in about 25% of patients with MF [65]. Our results
indicate that Bcl3 induces the expression of the pro-survival genes
cIAP1 and cIAP2, while it concomitantly inhibits the expression of the
pro-inﬂammatory cytokines IL-8 and IL-17 in CTCL cells (Fig. 8).
Unlike other members of IκB family, Bcl3 contains a transactivation
domain, and can be recruited to promoters, resulting in transcriptional
activation or repression depending on the transcriptional complex
[58–60]. We have found that Bcl3 is recruited not only to the NFκB
binding sites of the pro-survival genes cIAP1 and cIAP2, but also to the
pro-inﬂammatory cytokines IL-8 and IL-17 in CTCL cells, and that pro-
teasome inhibition by BZ inhibits this recruitment (Fig. 4). Interestingly
however, while proteasome inhibition and the resulting decreased Bcl3
promoter occupancy are associated with the decreased expression of
cIAP1 and cIAP2, they concurrently increase the expression of IL-8 and
IL-17. Even though the release of IL-8 and IL-17 from untreated CTCL
Hut-78 and HH cells is barely detectable, which is a hallmark of the ad-
vanced stages of CTCL, the suppression of Bcl3 by siRNA (Fig. 3) or BZ
(Fig. 5) increases their release to about 60 and 15 pg/ml, respectively.
While these IL-8 and IL-17 levels are lower compared to the release
from stimulated inﬂammatory cells or during chronic inﬂammatory
disorders, they correspond to the physiological levels in healthy donors
[55–57]. Our results show that IL-8 and IL-17, at the BZ-induced con-
centrations, inhibit the viability of Hut-78 cells (Fig. 5E, F), indicating
that the BZ-induced IL-8 and IL-17 might contribute to the previously
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it seems likely, that the BZ-induced IL-8 and IL-17 might have also a
paracrine effect, and regulate the viability and function of neutrophils,
PBMC, and other leukocytes.
Bortezomib is the ﬁrst clinically approved proteasome inhibitor that
has been very effective in the treatment of multiple myeloma, and has
shown promising results in other hematological malignancies as well,
including CTCL [25–31]. One of the main mechanisms of BZ function
is the inhibition of inducible NFκB activity and the expression of NFκB-
dependent genes [25–27]. Interestingly however, recent studies have
demonstrated that the proteasome inhibition has a differential effect
on the expression of NFκB-dependent genes. While some NFκB-
regulated genes are inhibited, some are unaffected, and some genes
are in fact increased by the proteasome inhibition [31–35]. We havepreviously shown that while the BZ-mediated proteasome inhibition
does not affect the expression of Bcl2 that is regulated predominantly
by p50/50 homodimers, it decreases the expression of cIAP1 and
cIAP2 regulated by p65/p50 heterodimers, resulting in increased CTCL
apoptosis [33]. Our present data show that in addition to the inhibition
of cIAP1 and cIAP2 expression, BZ induces the expression of IL-8 and IL-17
in CTCL cells, and increases their cellular levels to those seen in healthy
adults (Fig. 5). Furthermore, our results indicate that the BZ effect on the
expression of these NFκB-dependent genes is mediated through Bcl3
(Fig. 6).
Previous studies have suggested that Bcl3 forms transcriptional
complexes mainly with NFκB p50 and p52 subunits [58–60]. However,
our data indicate that Bcl3 does not regulate the transcription of Bcl2
(Fig. 3), which is regulated predominantly by p50/50 homodimers
AB
C                                
0
25
50
75
100
125
0 10 100
C
el
l v
ia
bi
lit
y 
(%
)
BZ (nM)
siRNA-control
siRNA-Bcl3
0
25
50
75
100
125
0 10 100
cI
A
P
1 
m
R
N
A
  (
%
U
T)
BZ (nM)
siRNA-control
siRNA-Bcl3
0
25
50
75
100
125
0 10 100
B
cl
3 
m
R
N
A
  (
%
U
T)
BZ (nM)
siRNA-control
siRNA-Bcl3
0
25
50
75
100
125
0 10 100
B
cl
2 
m
R
N
A
  (
%
U
T)
BZ (nM)
0
200
400
600
800
0 10 100
IL
-1
7 
m
R
N
A
  (
%
U
T)
BZ (nM)
0
25
50
75
100
125
0 10 100
cI
AP
2 
m
R
N
A
  (
%
U
T)
BZ (nM)
0
200
400
600
0 10 100
IL
-8
 m
R
N
A
  (
%
U
T)
BZ (nM)
siRNA-control
siRNA-Bcl3
Bcl3
Actin
siRNA-control siRNA-Bcl3
BZ (nM)   0  10   100 0    10  100
Fig. 6. Bcl3mediates the BZ-induced IL-8 and IL-17 expression, and cIAP1 and cIAP2 inhibition inHut-78 cells. (A) Suppression of Bcl3mRNA (top left panel) and protein (lower left panel)
levels by Bcl3 siRNA decreases viability in BZ-treated Hut-78 cells, measured by Trypan Blue exclusion (right panel). (B) Real time RT-PCR analysis of cIAP1, cIAP2 and Bcl2 mRNA levels
in Hut-78 cells transfectedwith control siRNA (full columns) or Bcl3 speciﬁc siRNA (empty columns) and treated 24 hwith 0, 10 and 100 nMBZ. (C) Real time RT-PCR analysis of IL-8 and
IL-17 mRNA levels in Hut-78 cells transfected with control siRNA (full columns) or Bcl3 speciﬁc siRNA (empty columns) and treated 24 h with 0, 10 and 100 nM BZ. The values represent
the mean ± SE of four experiments. Asterisks denote a statistically signiﬁcant (p b 0.05) change compared to cells transfected with the corresponding control siRNA.
2627T.-P. Chang, I. Vancurova / Biochimica et Biophysica Acta 1843 (2014) 2620–2630[33]. Furthermore, our results indicate that Bcl3 regulates the transcrip-
tion of cIAP1 and cIAP2 genes (Fig. 3), which are regulated by p65/p50
heterodimers in CTCL cells [33]. These data suggest that the regulation
of NFκB-dependent genes by Bcl3 is more complex, and may include
additional transcription factors and co-regulators. This is further sup-
ported by the ﬁnding that Bcl3 promoter binding concomitantly
increases (cIAP1, cIAP2) and decreases (IL-8, IL-17) the expression of
NFκB-responsive genes (Fig. 3, 4). In this context, Bcl3 was shown to in-
teract also with other transcriptional regulators, including the AP-1
transcription factors c-Jun and c-fos, STAT1, histone deacetylase 1
(HDAC1), and peroxisome proliferator-activated receptor-γ [66–69].
In lung cells infected with respiratory virus, Bcl3 recruits HDAC1 to
the IL-8 promoter, resulting in the transcriptional repression of IL-8
[67]. Thus, it seems likely that Bcl3 mediates the recruitment ofadditional transcriptional regulators to the promoter regions of cIAP1,
cIAP2, IL-8 and IL-17 genes in CTCL cells, resulting in their activation
or repression depending on the recruited factor.
In this study, we have identiﬁed a new NFκB binding site (GGGACA
CCCC) in human Bcl3 promoter, located from−298 to−289 (Fig. 7B).
This site has a high homology to the consensus NFκB binding site, and
ChIP data demonstrate that NFκB p65 and p50 subunits are highly re-
cruited to this site in CTCL cells. Interestingly, however, in BZ-treated
CTCL cells, the p65 and p50 subunits are replaced by p52 NFκB
(Fig. 7C), indicating that the Bcl3 expression in CTCL cells is regulated
through NFκB subunit exchange on Bcl3 promoter. The increased p52
recruitment to Bcl3 promoter correlates with the increased nuclear
levels of p52 in BZ-treated cells (Fig. 7A). However, since p65 and p50
subunits are also present at high levels in the nucleus of BZ-treated
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pro-inﬂammatory genes IL-8 and IL-17, thus contributing to the high survival and immu-
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afﬁnity for Bcl3 promoter than the p65/p50 subunits. Our data support
a model where in untreated cells, the Bcl3 promoter is occupied
predominantly by p65/p50 heterodimers, resulting in the high Bcl3
expression; however, in BZ-treated cells, the p65/50 heterodimers are
replaced by p52 subunits, resulting in Bcl3 transcriptional repression
(Fig. 7D).
5. Conclusions
In conclusion, our study shows that Bcl3 is highly expressed in
Hut-78 and HH cells, and suggests that Bcl3 has a dual role in these
cells. On the one hand, Bcl3 is highly recruited to cIAP1 and cIAP2 pro-
moters, resulting in their high transcription, and likely contributing to
the high survival of CTCL cells. On the other hand, Bcl3 is recruited to
the IL-8 and IL-17 promoters, resulting in the IL-8 and IL-17 suppres-
sion, which may contribute to the immunosuppressive nature of CTCL
cells (Fig. 8). Together, our data indicate that Bcl3 has a pro-survival
and immunosuppressive role in CTCL cells, and identify Bcl3 as a new
potential target in the treatment of CTCL.
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